BMO Capital Remains Bullish on Eli Lilly & Co. (LLY) Following FDA Approval of Taltz
Tweet Send to a Friend
BMO Capital reiterated an Outperform rating and $95.00 price target on Eli Lilly & Co. (NYSE: LLY) following the FDA's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
